Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

KineMed and Bayer Healthcare to Discover New Therapeutic Applications for Candidates

  • KineMed and Bayer Healthcare signed an agreement to discover new therapeutic applications. "The collaboration with Bayer Healthcare is an important opportunity for us to discover new indications for promising compounds and to work with Bayer Healthcare to pursue clinical development,” comments David Fineman, president and CEO of KineMed.

    KineMed will identify new therapeutic utilities by applying its translational medicine technologies, AquaTag™ and KineMarker™. Once a disease target is established for a selected drug candidate, the companies will jointly determine the best development and commercialization path.

    “This is in fact,” points out Finemen, “the third indications discovery deal we have announced in the past year, each of which gives us the option to move into more advanced product development."

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »